Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.1968 EUR -1.85% Market Closed
Market Cap: 25.7m EUR

Wall Street
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.3876 EUR with a low forecast of 0.3636 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.3636 EUR
85% Upside
Average
Price Target
0.3876 EUR
97% Upside
Highest
Price Target
0.42 EUR
113% Upside
Gensight Biologics SA Competitors:
Price Targets
OPK
OPKO Health Inc
135% Upside
STTK
Shattuck Labs Inc
135% Upside
4597
Solasia Pharma KK
55% Upside
BCRX
BioCryst Pharmaceuticals Inc
71% Upside
688293
Shanghai OPM Biosciences Co Ltd
33% Upside
ALNY
Alnylam Pharmaceuticals Inc
8% Upside
4593
Healios KK
22% Downside
VTGN
VistaGen Therapeutics Inc
473% Upside

Revenue
Forecast

Revenue Estimate
Gensight Biologics SA

The compound annual growth rate of Gensight Biologics SA's revenue for the next 2 years is 75%.

N/A
Past Growth
75%
Estimated Growth
Estimates Accuracy
-55%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-74%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SIGHT's stock price target?
Price Target
0.3876 EUR

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.3876 EUR with a low forecast of 0.3636 EUR and a high forecast of 0.42 EUR.

What is Gensight Biologics SA's Revenue forecast?
Projected CAGR
75%

The compound annual growth rate of Gensight Biologics SA's revenue for the next 2 years is 75%.

Back to Top